Market research
CYCC Cyclacel Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 14M
- P/E ratio
- 0.0
- Analyst target
- 1
- Dividend yield
- 0.0%
- Beta
- 0.16
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US23254L6039
- Market cap
- 14M
- P/E ratio
- 0.0
- Analyst target
- 1
- Dividend yield
- 0.0%
- Beta
- 0.16
About
About Cyclacel Pharmaceuticals Inc
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CYCC discussion.
5 years, 4 months ago
Cyclacel Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 12.2% below its 200 day moving average.
From a valuation standpoint, the stock is 94.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 74.6.
Cyclacel Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 21.6% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 6.6% to $-1M since the same quarter in the previous year.
Based on the above factors, Cyclacel Pharmaceuticals, Inc gets an overall score of 1/5.